Long-Term Cardiac Safety and Tolerability of Fingolimod in Multiple Sclerosis: A Postmarketing Study
Long-Term Cardiac Safety and Tolerability of Fingolimod in Multiple Sclerosis: A Postmarketing Study Paolicelli et al. The Journal of Clinical Pharmacology; June 2015 Fingolimod is the first The following content is accessible for members only, please sign in.